Inter-relations between relapses, drug regimens and compliance with treatment in tuberculosis
- PMID: 1882114
- DOI: 10.1016/s0954-6111(06)80087-9
Inter-relations between relapses, drug regimens and compliance with treatment in tuberculosis
Abstract
The inter-relationships between relapse, treatment regimen and compliance in 1009 patients treated for tuberculosis between 1978 and 1987 are reported. Multiple linear logistic regression using relapse as the dependent variable was used because of the complex relationships between treatment, compliance, age and calendar year of treatment. Compliance (P less than 0.0001) was the major determinant of relapse, but age (P = 0.047) was also significantly associated. Relapse was not related to sex, site of disease, ethnic group or the presence of multiple disease sites. Although the regimen given, the total duration of treatment and treatment with or without pyrazinamide were not statistically associated with relapse, pyrazinamide containing regimens were associated with better compliance. Compliance was best in those aged 60 years and over and worst in those aged 15-29 years. Some of the non-compliance leading to relapse was only uncovered by close Health Visitor surveillance and not by the physician supervising treatment, emphasizing the important role of field staff in patient follow-up.
Comment in
-
Epidemiological differences in pulmonary tuberculosis non-compliance and relapse.Respir Med. 1992 Mar;86(2):173-4. doi: 10.1016/s0954-6111(06)80241-6. Respir Med. 1992. PMID: 1615187 No abstract available.
Similar articles
-
A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis.Pediatr Infect Dis J. 1990 Nov;9(11):802-6. doi: 10.1097/00006454-199011000-00004. Pediatr Infect Dis J. 1990. PMID: 2263428 Clinical Trial.
-
[Compliance, efficacy and tolerability of the therapeutic regimen recommended by National Consensus on Tuberculosis].Enferm Infecc Microbiol Clin. 1997 Mar;15(3):129-33. Enferm Infecc Microbiol Clin. 1997. PMID: 9235051 Clinical Trial. Spanish.
-
Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis.Int J Tuberc Lung Dis. 1997 Oct;1(5):446-53. Int J Tuberc Lung Dis. 1997. PMID: 9441100 Clinical Trial.
-
Standard therapy for tuberculosis 1985.Chest. 1985 Feb;87(2 Suppl):117S-124S. doi: 10.1378/chest.87.2.117s. Chest. 1985. PMID: 3881230 Review.
-
Treatment of tuberculosis.Am Fam Physician. 1991 Jul;44(1):219-24. Am Fam Physician. 1991. PMID: 2058533 Review.
Cited by
-
Rethinking intercurrent events in defining estimands for tuberculosis trials.Clin Trials. 2022 Oct;19(5):522-533. doi: 10.1177/17407745221103853. Epub 2022 Jul 19. Clin Trials. 2022. PMID: 35850542 Free PMC article.
-
Monitoring treatment of patients with pulmonary tuberculosis: can PCR be applied?J Clin Microbiol. 1999 Nov;37(11):3601-7. doi: 10.1128/JCM.37.11.3601-3607.1999. J Clin Microbiol. 1999. PMID: 10523560 Free PMC article.
-
The challenge of re-treatment pulmonary tuberculosis at two teaching and referral hospitals in Uganda.Afr Health Sci. 2007 Sep;7(3):136-42. doi: 10.5555/afhs.2007.7.3.136. Afr Health Sci. 2007. PMID: 18052866 Free PMC article.
-
Treatment and recurrence on re-treatment tuberculosis patients: a randomized clinical trial and 7-year perspective cohort study in China.Eur J Clin Microbiol Infect Dis. 2020 Jan;39(1):93-101. doi: 10.1007/s10096-019-03696-8. Epub 2019 Dec 5. Eur J Clin Microbiol Infect Dis. 2020. PMID: 31807989 Clinical Trial.
-
Relapse more common than reinfection in recurrent tuberculosis 1-2 years post treatment in urban Uganda.Int J Tuberc Lung Dis. 2013 Mar;17(3):361-7. doi: 10.5588/ijtld.11.0692. Int J Tuberc Lung Dis. 2013. PMID: 23407224 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical